CSL Limited vaccine offshoot Seqirus has flagged a Therapeutic Goods Administration application for its new quadrivalent Flucelvax QIV, which has been found to be significantly more effective than traditional egg-based vaccines.
An investor update yesterday saw the company release data from a retrospective study of H3N2 cell seed versus egg-based vaccines in the USA, showing a 36% reduction in "influenza-like illness".
Approval may take some time, with Flucelvax QIV anticipated to become available here by 2020.
Other milestones expected next year include the approval of Afluria QIV for children aged 6 months to four years, while Seqirus also expects to lodge a submission for a quadrivalent version of its Fluad immunisation for seniors.
The company said it would double the capacity of its plant in Holly Springs, North Carolina to 50 million doses annually by spending US$140m on new equipment
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 18